Evaluating patient preferences for treating localised prostate cancer

An evaluation of patient preferences for the treatment of localised prostate cancer

Men with localised prostate cancer have to choose between active surveillance and radical therapy, which can entail a variety of treatment options from radiotherapy to surgery or minimally invasive interventions. This study applies a discrete choice experiment to elicit men’s preferences for, and trade-offs between, the attributes of pre-treatment evaluation, treatment and post-treatment follow-up for several available treatments. The study also investigates how subjects’ characteristics affect their treatment preference.

Outcome and Translation

The available treatments have minimal differences in terms of mortality. This study added to the evidence about how men with localised prostate cancer trade-off the differences between the treatment process and side effects.

HERU researchers involved in this research project: Verity Watson, Divine Ikenwilo and Nicolas Krucien

External collaborators: Hashim Ahmed and Mark Emberton (UCL)

Publications

Watson, V., McCartan, N., Krucien, N., Abu, V., Ikenwilo, D., Emberton, M. and Ahmed, H.U. (2020) 'Evaluating the trade-offs men with localised prostate cancer make between the risks and benefits of treatments: the COMPARE study', Journal of Urology, 204(2), 273-280.

Presentations

Ahmed, H.U., Watson, V., McCarten, N., Krucien, N., Abu, V., Ikenwilo, D. and Emberton, M. (2018) 'Evaluating the trade-offs men with localised prostate cancer make between the risks and benefits of treatments: the COMPARE study', National Cancer Research Institute Cancer Conference, Scottish Event Campus, Glasgow, 3-5 November 2018.

Watson, V., McCarten, N., Krucien, N., Abu, V., Ikenwilo, D., Emberton, M. and Ahmed, H.U. (2019) 'Evaluating the trade-offs men with localised prostate cancer make between the risks and benefits of treatments: the COMPARE study', 7th Annual Research Symposium: Evidence for Value in an Era of Realistic Medicine, COSLA Conference Centre, Edinburgh, 25 April 2019.